Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603926 · ClinicalTrials.gov registry record · Phase 2
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
A Phase 2 study, sponsored by Randi J. Hagerman, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02603926 is a Phase 2 study that has completed, run by Randi J. Hagerman, MD. The registered enrollment target is 6 participants.
The verdict
NCT02603926, a Phase 2 study, has completed, sponsored by Randi J. Hagerman, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
Interventions
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603926
The ClinicalTrials.gov registry entry for NCT02603926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Randi J. Hagerman, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopregnanolone is the first listed.
NCT02603926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603926 about?
NCT02603926 is a clinical study titled "Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone". The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
What is the current status of trial NCT02603926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02603926?
The interventions under investigation include: Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT02603926?
This trial is sponsored by Randi J. Hagerman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.